Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.624
-0.186 (-3.86%)
Streaming Delayed Price
Updated: 3:24 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
101,047
Open
4.780
Bid (Size)
4.610 (9)
Ask (Size)
4.630 (7)
Prev. Close
4.810
Today's Range
4.620 - 4.800
52wk Range
1.535 - 6.400
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
October 18, 2024
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in...
Via
Benzinga
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
October 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Performance
YTD
+12.79%
+12.79%
1 Month
-2.03%
-2.03%
3 Month
-6.01%
-6.01%
6 Month
+1.41%
+1.41%
1 Year
+104.62%
+104.62%
More News
Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
October 03, 2024
Via
Benzinga
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
September 30, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
Via
Benzinga
Exposures
Product Safety
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
September 25, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
August 29, 2024
From
2seventy bio
Via
Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 07, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
August 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
3 Hidden Stock Gems That Wall Street Is Overlooking
July 05, 2024
Via
InvestorPlace
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
June 27, 2024
Via
Benzinga
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
June 26, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
May 23, 2024
From
2seventy bio, Inc.
Via
Business Wire
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 08, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 03, 2024
From
2seventy bio, Inc.
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Via
Benzinga
Exposures
Product Safety
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
April 05, 2024
Via
Benzinga
Exposures
Product Safety
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
April 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
April 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
March 20, 2024
From
2seventy bio, Inc.
Via
Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 18, 2024
Via
Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 18, 2024
Via
Benzinga
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
March 18, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.